TetraLogic Pharmaceuticals to price initial public offering of stock

Proceeds used for clinical and pre-clinical development of birinapant

By Devika Patel

Knoxville, Tenn., Oct. 23 - TetraLogic Pharmaceuticals Corp. will price an initial public offering of common stock with a 30-day greenshoe, according to a Form S-1/A filed Wednesday with the Securities and Exchange Commission.

Oppenheimer & Co. is the bookrunning manager.

Proceeds will be used to advance the clinical and pre-clinical development of birinapant, for other clinical programs, for working capital and for general corporate purposes.

The clinical-stage biopharmaceutical company is based in Malvern, Pa. The company expects its shares will trade on the Nasdaq under the symbol "TLOG."

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.